patent.fyi
Applications  /  US 2026/0355357
United States Patent Application Publication

US 2026/0355357 A1

Published
Nov 12, 2026
Filed
Jun 18, 2026
Earliest date on the face
Dec 21, 2023
Classification
A61K 49/10
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Mass spectrometry of tissue

What ifWhat if deuterium-labeled 2DG and its phosphorylated metabolite are measured in a tissue extract by mass spectrometry?
Claim language“magnetic resonance (MR)2H spectrum”

Liquid chromatography separates 2DG and 2DG-6-phosphate in the tissue extract. A high-resolution mass spectrometer measures the labeled forms by their mass-to-charge ratios, and calibration samples relate peak areas to concentrations.

1.1Positron emission imaging

What ifWhat if a positron emission scanner maps tracer uptake after administration of a 2DG derivative carrying both deuterium and a positron-emitting fluorine isotope?
Claim language“at least one MR 2H image”

The administered derivative is 2-fluoro-2-deoxy-D-glucose with fluorine-18 at carbon 2 and carbon-bound deuterium at carbon 6. A detector ring records pairs of annihilation photons in coincidence, and reconstruction produces a spatial map of fluorine-18 activity.

1.1Tracer measurement by gas chromatography

What ifWhat if serial blood samples provide the time course of circulating deuterium-labeled 2DG through gas chromatography and mass spectrometry?
Claim language“magnetic resonance (MR)2H spectrum”

Sample preparation removes plasma proteins and converts 2DG hydroxyl groups to volatile trimethylsilyl derivatives. Gas chromatography separates the derivatives, and the mass spectrometer monitors fragment ions that retain the carbon-bound deuterium.

1.2Deuterated glucose for metabolic imaging

What ifWhat if the administered substrate is D-glucose labeled with two deuterium atoms at carbon 6?
Claim language“a 2-deoxy-D-glucose (2DG) compound”

Cells take up the labeled glucose and metabolize it through glycolysis, transferring deuterium into products such as lactate. Deuterium magnetic resonance spectroscopy resolves signals from the substrate and detectable products by their chemical shifts.

1.2Deuterated acetate as substrate

What ifWhat if the administered substrate is sodium acetate with three deuterium atoms on its methyl group?
Claim language“a 2-deoxy-D-glucose (2DG) compound”

Cells convert the labeled acetate to acetyl coenzyme A, which enters the citric acid cycle. Serial deuterium magnetic resonance spectra track the acetate signal and label appearing in downstream glutamate and glutamine.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Uptake mapping in perfused tissue constructs

A tissue engineering test system holds a cell-seeded scaffold in a flow chamber within a deuterium magnetic resonance coil. A pump delivers culture medium containing deuterated 2-deoxy-D-glucose through the scaffold. Spatially encoded deuterium spectra acquired during perfusion and after a switch to tracer-free medium show where labeled compounds persist in the scaffold.

Component substitution

Carbon-13 tracer and receiver substitution

Carbon-13-labeled 2-deoxy-D-glucose replaces the deuterated tracer, and a carbon-13 transmit and receive coil replaces the deuterium coil. The scanner acquires a localized carbon-13 spectrum from the region of interest before and after tracer administration. The preadministration spectrum supplies the background for estimating the change in signal at the labeled carbon resonance.

Parameter or scale variation

Serial spectra over forty minutes

A localized deuterium acquisition records a baseline spectrum from a fixed tissue volume before administration of deuterated 2-deoxy-D-glucose. Ten consecutive four-minute spectra follow administration with the same volume and receiver settings. Each measurement represents the mean signal over its acquisition window, and the resulting time series describes how the signal changes over forty minutes.

Combination with existing systems

Deuterium mapping with proton anatomical imaging

A dual-tuned proton and deuterium coil collects anatomical images and deuterium spectroscopic images in one scanner session after tracer administration. The proton acquisition defines tissue boundaries, and the deuterium acquisition samples tracer resonances in a coarser spatial grid. Reconstruction places both datasets in scanner coordinates and uses the fraction of each deuterium voxel within a proton-defined region to calculate regional signal averages.

Respiratory gating for abdominal deuterium mapping

A pneumatic belt measures breathing while a deuterium coil acquires abdominal spectroscopic imaging data after administration of deuterated 2-deoxy-D-glucose. The scanner records the respiratory waveform and timestamps each spatial encoding readout. The controller repeats readouts acquired outside a selected end-expiratory window, and reconstruction uses the accepted set to form the deuterium map.

Automated or data-driven variant

Automated spectral fitting with residual checks

Reconstruction software estimates frequency drift from the deuterated water resonance within a reference region and applies the resulting offset to the spectra from that acquisition. The software fits water and tracer resonances jointly using reference frequencies and an adjustable baseline. It exports fitted tracer peak areas and flags voxels with high fit residuals or wide uncertainty intervals.

Specific version of a part

Serial localized deuterium spectra

A deuterium-tuned radiofrequency coil acquires repeated spectra from the same selected tissue volume after administration. Integrating the tracer resonance in successive spectra produces a regional signal time course.

Three-dimensional deuterium spectroscopic imaging

A three-dimensional phase-encoded acquisition records a deuterium free induction decay for each spatial encoding step. Reconstruction generates a spectrum per voxel, and integrating the tracer resonance produces a volumetric signal map.

Single deuterium at carbon six

The administered 2DG contains one carbon-bound deuterium atom at carbon 6, giving a terminal CHDOH group. The other carbon-bound hydrogen at that position remains protium.

Two deuteriums at carbon six

The administered 2DG contains two carbon-bound deuterium atoms at carbon 6, giving a terminal CD₂OH group. Each tracer molecule contributes two deuterium nuclei at that position.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,182,788 B2
Published
May 22, 2012
Filed
Apr 23, 2003
Class
A61K 51/00
Document BUS 2022/0018922 A1
Published
Jan 20, 2022
Filed
Nov 20, 2019
Class
G01R 33/485
Claim 1
Document A
Document B
1.1acquiring at least one magnetic resonance (MR)2H spectrum and/or at least one MR 2H image from a subject
Volumetric echo planar spectroscopic imaging (EPSI) scans were performed on four healthy subjects and six subjects with newly diagnosed glioblastoma who were enrolled in an ongoing clinical trial (NCT03137888).
B · US 2022/0018922 A1 · ¶ 70
1.2wherein the subject has been administered with a 2-deoxy-D-glucose (2DG) compound comprising one or more isotopically substituted hydrogen atoms.
The present invention relates to a method for obtaining a 2-[18F]fluor-2-deoxy-D-glucose (also described herein as 18F-fluor-deoxy-glucose or 18F-FDG)-solution with improved physical/chemical characteristics, i.e. radiochemical stability, and a (sterile) 18F-FDG-solution thus obtained.
A · US 8,182,788 B2 · ¶ 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, the radiochemical purity of the compound decreases drastically during standard autoclaving steps and thus the compound fails to meet the specifications dictated by the European and United States Pharmacopeia.
A · US 8,182,788 B2 · ¶ 3
It has been surprisingly found that buffers based on a weak acid improve the physical/chemical characteristics, i.e. the radiostability, of a 18F-FDG-solution to such extent that it becomes possible to autoclave this solution and maintain a radiochemical purity of at least 95%.
A · US 8,182,788 B2 · ¶ 5
Thus, there is a need for timely and accurate imaging processing, including spectral fitting.
B · US 2022/0018922 A1 · ¶ 4
The systems and methods of the disclosure provide rapid and accurate spectral fitting for magnetic resonance spectroscopy data enabling spectral fitting and (in vivo) metabolite measurements that can be performed, for example, using a conventional computer.
B · US 2022/0018922 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355357 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355357/, SHA-256 95e558942368e7be0cd8d8ddb98c3103c35e1c6debdc0518c2a9919f4ffd0996
First published
Permanent addresshttps://patent.fyi/US20260355357/
Content fingerprint (SHA-256)95e558942368e7be0cd8d8ddb98c3103c35e1c6debdc0518c2a9919f4ffd0996
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi